Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, Fifth Annual
Given the increasing frequency of hematologic malignancies and the complexities of treatments with novel agents, particularly with immunotherapeutic approaches, there is a need to provide an opportunity for oncologists, hematologists, oncology nurses and pharmacists to engage in thoughtful discussions with experts in these fields. In addition, there is emerging data about the biology of these malignancies impacting optimal management of patients with these disorders. Clinical decision making and management therefore have become more complex.
This one-and-a-half-day symposium has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of leukemia, lymphoma, multiple myeloma and stem cell transplantation by novel immunotherapies and treatment combinations. Updates on evolving immunologically and molecular based system therapies will be profiled and discussed.
Agenda
Friday, March 8
| 7:30 - 8:00 a.m. | Product Theater |
| 8:00 - 8:30 a.m. | Registration and Breakfast |
| 8:30 - 8:45 a.m. | Welcome and Introductions Guenther Koehne, M.D., Ph.D. |
| Acute Myeloid Leukemia | |
| 8:45 – 9:15 a.m. | Acute Myeloid Leukemia in 2024 Richard Stone, M.D. |
| 9:15 – 9:45 a.m. | Targeted Therapies in Acute Myeloid Leukemia Eytan Stein, M.D. |
| Novel Approaches to Leukemia Therapies | |
| 9:45 – 10:15 a.m. | LYT-200, an Anti-Galectin-9 Antibody in Clinical Development for AML/High-risk MDS Aleksandra Filipovic M.D. Ph.D. |
| 10:15 – 10:45 a.m. | Immunotherapeutic Approaches to Undruggable Leukemia Targets David Scheinberg M.D., Ph.D. |
| 10:45 – 11:15 a.m. | Break and Exhibits |
| 11:15 – 11:45 a.m. | CD34+-selected Allografts as Platform for Post-Transplant CAR T-Cell Therapy in AML Guenther Koehne, M.D., Ph.D. |
| 11:45 – 12:15 p.m. | The Role of Haploidentical Transplants in 2024 Leo Luznik, M.D. |
| 12:15 – 12:45 p.m. | Myelofibrosis: Current and Emerging Treatments Raajit Rampal, M.D. |
| 12:45 – 1:15 p.m. | Lunch and Exhibits |
| 1:15 – 1:45 p.m. | Product Theater |
| Multiple Myeloma | |
| 1:45 – 2:15 p.m. | The Role of Auto SCT for Multiple Myeloma in 2024 Saad Usmani, M.D. |
| 2:15 – 2:45 p.m. | Targeted Therapies for Multiple Myeloma in 2024 Adam Cohen, M.D. |
| 2:45 – 3:15 p.m. | Optimizing the Management of Relapsed and Refractory Multiple Myeloma in the Era of Immunotherapy Paul Richardson, M.D. |
| 3:15 – 3:45 p.m. | Galectin-9 as a Therapeutic Primer to Boost Anti-SLAM7 Efficacy in Multiple Myeloma Charles Dimitroff, Ph.D. |
| 3:45 – 4:15p.m. | Break and Exhibits |
| Special Presentations | |
| 4:15 – 4:45 p.m. | Overview of Cellular and Immunotherapies in South America: Current Status and Unmet Needs Patricio Duarte, M.D. |
| 4:45 – 5:15 p.m. | Questions & Answers |
| 5:15 p.m. | Adjourn |
Saturday, March 9
| 7:30 – 8:00 a.m. | Product Theater |
| 8:00 – 8:30 a.m. | Registration and Breakfast |
| CAR T-Cell Therapies | |
| 8:30 – 9:00 a.m. | Next Steps in CAR T-Cell Therapies Michel Sadelain, M.D., Ph.D. |
| 9:00 – 9:30 a.m. | Do We Need a CAR T-Cell Registry? Marcelo Pasquini, M.D. |
| 9:30 – 10:00 a.m. | The Role of Intestinal Microbiome in Cancer Immunotherapy Marcel van den Brink, M.D., Ph.D. |
| Acute Leukemia | |
| 10:00 – 10:30 a.m. | Developing Next Generation T-Cell Therapies for AML Catherine Bollard, M.D. |
| 10:30 – 11:00 a.m. | Break and Exhibits |
| 11:00 – 11:30 a.m. | Taking the Next Steps to Improving Outcomes in ALL Wendy Stock, M.D. |
| 11:30 – 12:00 p.m. | The Role of Allogeneic Hematopoietic Stem Cell Transplantation for ALL in 2024 Robert Soiffer, M.D. |
| Non-Hodgkin Lymphoma | |
| 12:00 – 12:30 p.m. | Updates on Treatment Approaches in Diffuse Large B-Cell Lymphoma (DLBCL) Matthew Matasar, M.D. |
| 12:30– 1:00 p.m. | CAR T-Cell Therapies for NHL Craig Sauter, M.D. |
| 1:00 – 1:15 p.m. | Questions & Answers |
| 1:15 p.m. | Adjourn |
NOTE: Schedule subject to change.
JW Marriott Miami
1109 Brickell Avenue
Miami, Florida 33131
United States
+1 (305) 329-3500
About the Venue
The JW Marriott Miami is located in the heart of Brickell, Miami's trendy destination for dining, shopping, and nightlife and is located a short walk away from the popular shopping and entertainment destination, Brickell City Centre. Guests are not far from all that Miami has to offer including the Perez Art Museum, Frost Science Museum, Kaseya Center (home of the Miami Heat), Adrienne Arsht Center, Port of Miami, South Beach, Coral Gables, Coconut Grove and Miami International Airport.
Rooms Rates and Highlights
- Special group rates starting from $379 USD per night, plus taxes/fees
- 24-hour room service - Free Wi-Fi for Marriott Bonvoy members - Complimentary fitness center access - Spa - Pool - Business Center
Travel Information
The drive time between the JW Marriott Miami and Miami International Airport (MIA) is around 20 minutes and covers a distance of around 8.2 miles.
Services + Amenities
Relax with a facial or full body massage by an expert therapist at Salus Spa. Afterward, continue to unwind in the warmth of the Miami sun at the JW Marriott Miami's stainless steel sky pool.
Adjacent to The Spa is our Fitness Studio, the perfect escape for an energizing workout, featuring state-of-art equipment and free weights.
Dining
Isabela's
With its natural light and views of Brickell Ave, Isabela's is the perfect place to start the day.
La Terraza Cafe & Bar
With its Plasma TV's and LED Screens tuned to popular sporting events & delicious casual fare served at lunch, dinner, and weekend Brunch makes La Terraza the ideal place to unwind with friends and family.
Downtown Miami and Brickell
Greater Miami is synonymous with beautiful beaches and towering palm trees - but in its urban center, it is the cityscape of glittering skyscrapers over Biscayne Bay that gets all the attention. Diverse, dynamic and densely populated, Downtown Miami and the adjoining Brickell area is a hub of international finance, dining, arts and entertainment that no visitor should miss.
| ⚠ | COVID-19 Protocols for All Attendees, Exhibitors and VendorsProof of COVID-19 vaccination or negative COVID-19 test is no longer required to attend a Baptist Health CME conference or symposium. Baptist Health's in-person COVID-19 policy is subject to change based on COVID-19 community levels and any updated guidance from CDC and/or federal or state officials in localities hosting a Baptist Health in-person meeting or event. Baptist Health reserves the right to modify its COVID-19 related procedures and health screening protocols in its sole discretion at any time. Participants will be informed of any such changes on an ongoing basis. Masks are welcome but not required. Please understand and respect that wearing a mask is a personal and individual choice of your fellow conference attendees. Masks will made available for attendees onsite at conferences upon request. |
Symposium Director
Deputy Director
Chief, Blood and Marrow Transplant and Hematologic Oncology
Miami Cancer Institute
Miami, Florida
Faculty
Director, Center for Cancer and Immunology
Director, Program for Cell Enhancement and Technologies for Immunotherapy
Interim Chair, Department of Pediatrics
Interim Director, Children's National Research Institute
Interim Executive Vice President & Chief Academic Officer
Children's National Hospital
Washington, D.C.
Associate Professor of Medicine
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Executive Associate Dean for Research
Director, Translational Glycobiology Institute
Professor, Department of Translational Medicine
Herbert Wertheim College of Medicine
Florida International University
Miami, Florida
Associate Professor of Hematology
Instituto Universitario CEMIC
Bueno Aires, Argentina
Department of Surgery and Cancer
Imperial College of London
London, England
Professor of Oncology
Johns Hopkins Medicine
Baltimore, Maryland
Chief, Division of Blood Disorders
Rutgers CINJ and RWJBarnabas Health
Professor of Medicine, Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Medical Oncologist
Medical College of Wisconsin
Milwaukee, Wisconsin
Associate Member
Clinical Director
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Director
Center for Cell Engineering
Memorial Sloan Kettering Cancer Center
New York, New York
Hematology and Medical Oncology
Director, Blood and Marrow Transplant Program
Cleveland Clinic Main Campus
Cleveland, Ohio
Director, Experimental Therapeutics Center
Deputy Director, SKI for Therapeutic Discovery
Memorial Sloan Kettering Cancer Center
New York, New York
Chief, Division of Hematologic Malignancies
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Assistant Attending Physician
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Anjuli Seth Nayak Professor of Leukemia Research
Section of Hematology/Oncology
University of Chicago Medicine and Comprehensive Cancer Center
Chicago, Illinois
Chief of Staff, Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Chief of Myeloma Service Chief
Attending Physician, Myeloma, Cellular Therapy and Adult BMT
Memorial Sloan Kettering Cancer Center
New York, NY
Medical Oncologist
Head, Division of Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York
NOTE: Faculty subject to change.
Disclosures and Resolution of Conflict of InterestDisclosure Policy and Disclaimer
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for a total of 11.25 credit hours. Day 1 - 7 hours CE Broker Course #20-1177474, Day 2 - 4.25 hours CE Broker Course #20-1177480, by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 11.0 credit hours for Nurse Practitioners, Nurses, Laboratory Personnel and Respiratory Therapists. Day 1 - 7 hours CE Broker Course #20-1177474, Day 2 - 4. hours CE Broker Course #20-1177480, Baptist Health South Florida CE Broker Provider #50-182.
This activity has also been approved for 11.25 for Pharmacists and Techs. Day 1 - 7 hours CE Broker Course #20-1177474, Day 2 - 4.25 hours CE Broker Course #20-1177480, Baptist Health South Florida CE Broker Provider #50-182.
The American Academy of Nurse Practitioners Certification Board (AANPCB) accepts CEs accredited by the ACCME. Individuals are responsible for checking with the AANPCB for further guidelines.
AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC©) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC©). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Disclaimer
Baptist Health South Florida presents this CME activity for use by healthcare professionals for educational purposes only. Opinions, perspectives and information presented by the faculty represent their ideas and views, and participants should carefully consider all available scientific data before acting on knowledge gained through this activity. Additionally, participants should consult the US Food and Drug Administration (FDA) for approved uses prior to prescribing medications or utilizing medical devices discussed in this activity.
While Baptist Health makes reasonable efforts to ensure that accurate information is presented, no warranty, expressed or implied, is offered. Participants should rely on their own clinical judgment, knowledge and experience before applying information acquired to their professional use.
We gratefully acknowledge the following exhibitors:
Abbvie
Abbvie/Pharmacyclics
Adaptive Biotechnologies
ADC Therapeutics
Agios Pharmaceuticals
Amgen Oncology Rare Disease
Astellas Oncology
AstraZeneca
Beigene
Blueprint Medicines
Bristol-Myers Squibb
CTI Biopharma
Daiichi Sankyo
Florida Society of Clinical Oncology (FLASCO)
Genentech
GlaxoSmithKline
Incyte
Jazz Pharmaceuticals
Kite Pharma
Lilly Oncology
Merck
Miami Cancer Institute
Novartis Pharmaceuticals
Omeros Corporation
Pfizer Oncology
Pharmacosmos Therapeutics
PureTech Health
Recordati Rare Diseases
Rigel Pharmaceuticals
Sanofi/Kadmon
Sanofi Rare Disorders
Sanofi Rare Blood Disorders-Specialty Care.
Stemline Therapeutics
Taiho Oncology
Takeda Oncology
We welcome the following companies as first-time exhibitors:
Bioline RX
Genmab
Ipsen Biopharmaceuticals
Kyowa Kirin
Notable Labs
Sobi